Teicoplanin was evaluated in 37 patients with gram-positive bacteremia in an open study. The bacteremia resulted from endocarditis (13 patients), wound infection (nine patients), central venous catheter (five patients), arthritis (two patients), and ventriculoperitoneal shunt (one patient). In seven patients the origin of the bacteremia was unknown. Pathogens isolated from the blood included Staphylococcus aureus (21 strains), Staphylococcus epidermidis (seven strains), Staphylococcus hemolyticus (one strain), nongroupable Streptococcus species (four strains), Enterococcus fecalis (three strains), Enterococcus avium (one strain), Streptococcus group A (one strain), Streptococcus group B (one strain), Streptococcus sanguis (one strain), Streptococcus bovis (one strain), and Aerococcus viridans (one strain). Teicoplanin was administered intravenously once daily at a mean dose of 7.3 mg/kg (range, 4.2 to 13.6 mg/kg) for a mean duration of 20.3 days (range, 2 to 42 days). Nine patients received teicoplanin in combination with other antibiotics, mainly aminoglycosides. Overall 30 patients (81%) were cured, four patients (10.8%) had a superinfection with gram-negative bacilli, and three patients (8.1%) did not respond to the treatment. Clinical cure was observed in 11 of 13 cases of endocarditis. Thirty-nine of 42 gram-positive isolates were eradicated (92.8%). Side effects were seen in two patients (5.4%). These data show that teicoplanin is a safe and effective agent for the treatment of gram-positive bacteremia, including septic endocarditis.
|Number of pages||11|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1992|
ASJC Scopus subject areas